GlassScriptPhysician profile
Jignesh S Patel
NPI 1447753306
$4,151.77
in general payments reported to CMS, 2019-2025
36 companies · $993 in 2025
The $993 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $623 · 2022: $643 · 2023: $980 · 2024: $913 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,874 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,874.40 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $608.99 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $462.14 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $436.30 | 2021-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $400.13 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $379.60 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $377.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $238.53 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $156.02 | 2023-2025 | Edarbyclor, Edarbyclor, Edarbi |
| Sanofi-Aventis U.S. LLC | $151.44 | 2022-2023 | |
| Corcept Therapeutics | $135.11 | 2025 | Korlym |
| Abbott Laboratories | $126.24 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $68.47 | 2022-2023 | Seglentis |
| Scilex Pharmaceuticals INC. | $60.25 | 2024 | |
| Nestle Healthcare Nutrition INC. | $51.23 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.17 | 2022-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $46.14 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $37.15 | 2023-2024 | |
| Hologic Sales and Service, LLC | $33.25 | 2024 | Aptima |
| Cequr Corporation | $31.55 | 2024 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $31.11 | 2023 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $28.59 | 2021 | |
| Merck Sharp & Dohme LLC | $28.11 | 2021-2023 | Steglatro, Belsomra |
| Verity Pharmaceuticals INC. | $18.99 | 2024 | Tlando |
| Medicomp INC | $17.49 | 2025 | Telepatch Cardiac Monitor |
| Shield Therapeutics INC | $17.49 | 2025 | |
| Sumitomo Pharma America, INC. | $17.10 | 2025 | Gemtesa |
| Vertex Pharmaceuticals Incorporated | $16.97 | 2025 | |
| Mannkind Corporation | $15.58 | 2022 | |
| Currax Pharmaceuticals LLC | $15.00 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.00 | 2021 | |
| Amarin Pharma, INC. | $14.40 | 2021 | |
| Eisai INC. | $13.64 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.63 | 2021 | |
| Lifescan, INC. | $13.59 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.35 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jignesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.